ArticleCritical care explorations2022
Risk Factors and Clinical Outcomes of Candidemia Associated With Severe COVID-19.
Article in Critical care explorations, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.
- Candidemia Following Severe COVID-19 in Hospitalised and Critical Ill Patients: A Systematic Review and Meta-Analysis.Mycoses · 2024Pooled it
- Clinical Determinants of 30-Day Mortality in Candidemia: Antifungal Susceptibility and Treatment Patterns in a 10-Year Cohort.Antibiotics (Basel, Switzerland) · 2026Article
- Candidemia in the intensive care unit before and during the COVID-19 pandemic: a cross-sectional analysis.IJID regions · 2026Article
- Trends in Candidemia Over the Last 14 Years: A Comparative Analysis ofOpen forum infectious diseases · 2025Article
- Neutrophil extracellular traps capture the human pathogen, Candida albicans, in blood and delay hyphal transformation.Journal of leukocyte biology · 2025Article
- Comparison of clinical characteristics and outcomes in candidaemia patients with and without COVID-19: a multicentre retrospective study.BMC infectious diseases · 2024Article
- Candidemia chronicles: Retrospective analysis of candidemia epidemiology, species distribution, and antifungal susceptibility patterns in Bahrain.World journal of virology · 2024Article
- Relationship between SARS-CoV-2 infection and ICU-acquired candidemia in critically ill medical patients: a multicenter prospective cohort study.Critical care (London, England) · 2024Article
- Epidemiological Assessment and Risk Factors for Mortality of Bloodstream Infections byJournal of fungi (Basel, Switzerland) · 2024Article
- Risk analysis of candidemia and its effect on mortality in COVID 19 and non COVID 19 patients.Iranian journal of microbiology · 2024Article
- Article
- Outcomes of Patients with COVID-19 and Fungal Coinfections: A Systematic Review and Meta-Analysis Study.Iranian journal of pathology · 2024Review
- Blood Stream Infections in COVID-19 Patients From a Tertiary Care Center in Lebanon: Causative Pathogens and Rates of Multi-Drug Resistant Organisms.Mayo Clinic proceedings. Innovations, quality & outcomes · 2023Article
- The Clinical Characteristics of Bloodstream Infections Due toJournal of fungi (Basel, Switzerland) · 2023Article
- Yeast Bloodstream Infections in the COVID-19 Patient: A Multicenter Italian Study (FiCoV Study).Journal of fungi (Basel, Switzerland) · 2023Article
- High Incidence of Candidemia in Critically Ill COVID-19 Patients Supported by Veno-Venous Extracorporeal Membrane Oxygenation: A Retrospective Study.Journal of fungi (Basel, Switzerland) · 2023Article
- Risk factors and outcomes of fungal superinfections in patients with severe COVID-19: an observational study from Pisa academic hospital.Le infezioni in medicina · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 7 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
COVID-19 can cause serious illness requiring multimodal treatment and is associated with secondary infections. Studies have suggested an increased risk of fungal infections, including candidemia following severe COVID-19 though understanding of risk factors and clinical outcomes remains unclear.
objectivesTo describe clinical characteristics, outcomes and risk factors of candidemia among patients hospitalized with severe COVID-19. DESIGN SETTING AND
participantsA multicenter, case-control study of patients with severe COVID-19 was conducted to evaluate risk factors and clinical outcomes in patients who developed candidemia between August 2020 and August 2021. MAIN OUTCOMES AND MEASURES: Chart review evaluating institutional and patient demographics, clinical and mycological characteristics, concomitant interventions (antibiotics, immunosuppressive agents, parenteral nutrition, degree of oxygen support, mechanical ventilation, surgery), treatment regimens, and outcomes (length of stay and discharge disposition).
resultsA total of 275 patients were enrolled in the study, including 91 patients with severe COVID-19 and subsequent candidemia and 184 with severe COVID-19 without candidemia. Most patients received antibiotics prior to candidemia episode (93%), while approximately one-quarter of patients received biologic for COVID-19. In-hospital mortality was significantly higher in the cases compared with the controls (68% vs 40%; CONCLUSIONS AND RELEVANCE: Candidemia following COVID-19 infection is a concern that requires clinical consideration and patient monitoring. Risk factors for the development of candidemia in the setting of COVID-19 infection are largely consistent with traditional risk factors for candidemia in hospitalized patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.